Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | RPA1 | P27694 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985510 | 0.98 | RAB9A (0.64) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL25430210 | 0.91 | RAB9A (0.79) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL19131260 | 0.91 | RAB9A (0.79) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL1250289 | 0.89 | NPC1 (0.55) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL9047596 | 0.89 | MAPT (0.66) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL9049682 | 0.89 | MAPT (0.66) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL1251703 | 0.85 | APP (0.52) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL8490480 | 0.85 | AXL (0.64) | RAB9APOLBNPC1MEN1KMT2A | |
| SCHEMBL1607990 | 0.85 | RAB9A (0.84) | RAB9ANPC1MEN1KMT2AALOX15 | |
| SCHEMBL1608926 | 0.85 | RAB9A (0.52) | RAB9APOLBNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | claimed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | APP, PSEN1, BACE1 | RAB9A 4026/4885POLB 4594/4885NPC1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.